Artwork

Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Genitourinary Cancers — An Interview with Dr William K Oh on Recent Trial Updates

44:21
 
Share
 

Manage episode 478633562 series 1464352
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Featuring an interview with Dr William K Oh, including the following topics:

  • Use of secondary hormonal agents for patients with metastatic hormone-sensitive prostate cancer (0:00)
  • Data supporting the clinical activity of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) (11:10)
  • Radiopharmaceuticals for the treatment of mCRPC (16:53)
  • Available data on cabozantinib for mCRPC (24:38)
  • Cabozantinib combinations for advanced renal cell carcinoma (RCC) (26:17)
  • Subcutaneous nivolumab versus intravenous nivolumab for advanced RCC (30:00)
  • Addition of nivolumab to tivozanib compared to tivozanib alone in advanced relapsed/refractory RCC previously treated with an immune checkpoint inhibitor (31:28)
  • Long-term follow-up with belzutifan for relapsed/refractory advanced RCC (33:39)
  • Major findings from the NIAGARA study of perioperative durvalumab for muscle-invasive bladder cancer (MIBC) (35:44)
  • Data surrounding adjuvant immunotherapy for MIBC (38:07)
  • Clinical development of TAR-200 for high-risk non-muscle-invasive bladder cancer (39:44)
  • Updated analysis of EV-302 study of enfortumab vedotin in combination with pembrolizumab for previously untreated advanced urothelial cancer (UC) (41:06)
  • Implementation of emerging data in the treatment landscape of UC (41:56)

CME information and select publications

  continue reading

1514 episodes

Artwork
iconShare
 
Manage episode 478633562 series 1464352
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Featuring an interview with Dr William K Oh, including the following topics:

  • Use of secondary hormonal agents for patients with metastatic hormone-sensitive prostate cancer (0:00)
  • Data supporting the clinical activity of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) (11:10)
  • Radiopharmaceuticals for the treatment of mCRPC (16:53)
  • Available data on cabozantinib for mCRPC (24:38)
  • Cabozantinib combinations for advanced renal cell carcinoma (RCC) (26:17)
  • Subcutaneous nivolumab versus intravenous nivolumab for advanced RCC (30:00)
  • Addition of nivolumab to tivozanib compared to tivozanib alone in advanced relapsed/refractory RCC previously treated with an immune checkpoint inhibitor (31:28)
  • Long-term follow-up with belzutifan for relapsed/refractory advanced RCC (33:39)
  • Major findings from the NIAGARA study of perioperative durvalumab for muscle-invasive bladder cancer (MIBC) (35:44)
  • Data surrounding adjuvant immunotherapy for MIBC (38:07)
  • Clinical development of TAR-200 for high-risk non-muscle-invasive bladder cancer (39:44)
  • Updated analysis of EV-302 study of enfortumab vedotin in combination with pembrolizumab for previously untreated advanced urothelial cancer (UC) (41:06)
  • Implementation of emerging data in the treatment landscape of UC (41:56)

CME information and select publications

  continue reading

1514 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Listen to this show while you explore
Play